Clearmind Medicine Completes Preclinical Study for Alcohol Use Disorder Treatment
Ticker: CMND · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: preclinical-study, drug-development, alcohol-use-disorder
TL;DR
Clearmind Medicine's alcohol treatment study shows promise, no bad side effects in animals.
AI Summary
Clearmind Medicine Inc. announced on March 30, 2026, the successful completion of a preclinical study for its novel MEAI-based treatment for alcohol use disorder. The study demonstrated a significant reduction in alcohol consumption in animal models, with no observed adverse effects.
Why It Matters
This successful preclinical study is a crucial step towards developing a new therapeutic option for alcohol use disorder, potentially offering a novel treatment approach.
Risk Assessment
Risk Level: medium — The company is in the preclinical stage, meaning the treatment has not yet been tested in humans, and regulatory approval is a long way off.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer and subject of the report
- March 30, 2026 (date) — Filing date and period of report
- MEAI (drug_candidate) — Active compound in the preclinical study
- 0001892500 (company_id) — CIK number for Clearmind Medicine Inc.
FAQ
What was the primary outcome of the preclinical study announced by Clearmind Medicine?
The preclinical study demonstrated a significant reduction in alcohol consumption in animal models for its MEAI-based treatment.
What specific condition is Clearmind Medicine targeting with its MEAI-based treatment?
Clearmind Medicine is targeting alcohol use disorder with its novel MEAI-based treatment.
When did Clearmind Medicine file this report regarding the preclinical study?
Clearmind Medicine filed this report on March 30, 2026.
Were there any adverse effects observed in the preclinical study?
No adverse effects were observed in the animal models during the preclinical study.
What type of issuer is Clearmind Medicine Inc. according to this filing?
Clearmind Medicine Inc. is a foreign private issuer.
Filing Stats: 221 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2026-03-30 09:27:23
Filing Documents
- ea0284002-6k_clearmind.htm (6-K) — 10KB
- ea028400202ex99-1.htm (EX-99.1) — 10KB
- ea028400202_ex99-1img1.jpg (GRAPHIC) — 2KB
- 0001213900-26-036044.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: March 30, 2026 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3